Recent research identifies a specific molecular pathway—driven by HSF1 activation and increased cholesterol biosynthesis in smooth muscle cells—that explains why certain ACTA2 mutations predispose patients to premature atherosclerotic cardiovascular disease beyond traditional aortic risks.